top of page
Release Tx Announces iScience Publication on Encapsulated Cell Technology for Sustained, Localised Anti-CTLA-4 Cancer Immunotherapy
Peer-reviewed preclinical study in a colorectal cancer model demonstrates antitumour activity and immune modulation within the tumour despite substantially lower systemic antibody exposure than systemic ipilimumab, with lower systemic exposure associated with fewer observable signs of treatment-related toxicity. Release Therapeutics (Release Tx) is pleased to announce the publication of a new peer-reviewed preclinical study in iScience, a Cell Press journal, evaluating the us
17 hours ago9 min read
Release Therapeutics publishes cutting-edge research in Cell Press
Release Therapeutics publishes cutting-edge research in Cell Press
Jun 18, 20247 min read
Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model
AACR American Association for Cancer Research Orlando Florida Poster Grogg et al. 2023. iScience. Engineering a versatile and retrievable...
Oct 20, 20231 min read
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology
Molecular Therapy – Methods & Clinical Development Immortalized human myoblast cell lines for the delivery of therapeutic proteins using...
May 31, 20221 min read
bottom of page